CARLSBAD, Calif., May 10, 2011 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE), today
With the 7500 Fast Dx system, clinical laboratories and institutions in Japan that develop in vitro molecular diagnostic assays in oncology, genetic disease and infectious disease, will now be able to leverage the instrument's regulatory clearance to develop tests for clinical applications. Similarly, the 3500 Dx Series Genetic Analyzer is the first CE IVD- marked capillary electrophoresis system for nucleic acid analysis. It is intended for use in the analysis of human DNA or RNA for the detection of genetic changes that may lead to disease presence or susceptibility.
The 7500 enables labs to complete real-time PCR amplification and accurately and precisely quantify nucleic acids in less than 40 minutes. The instrument's software suite includes customizable security settings, and versatile security, auditing, and e-signature applications that allow users to record all instrument operations, supporting requirements of clinical laboratories to work in a secure environment.
The 3500 Dx Series enables scientists to run up to 1,100 sequencing or 1,200 genotyping samples per day. It features a novel consumables design that incorporates the ability to track key information with radio frequency identification (RFID) tags, new optical and thermal sub-systems, and redesigned data collection and analysis software, creating a more cost-effective method for high-quality data analyses.
"Life Technologies Japan is pleased to introduce these diagnostics platforms combining best-in-class technologies with easy-to-use, clinically-compliant interfaces," said Joydeep Goswami, Head of Life Technologies Japan. "These devices will enable physicians and laboratories to rapidly develop new clinical and diagnostic assays using a platform they are familiar with. We will work closely with the developers of these assays to assist them in bringing their assays to patients quickly and safely."
"Having these market-leading platforms available for IVD assay development significantly broadens the options for molecular diagnostic companies in Japan," adds Michael Paumen, Director at Life Technologies Japan. "Our flexible partnership programs will appeal to a wide variety of needs."
The 7500 Dx and 3500 Dx platforms are already widely available in many countries in Asia, North America and Europe.
About Life Technologies
Life Technologies Corporation is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, Gibco, Ambion, Molecular Probes and Taqman products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies ContactPatty Zamora email@example.com
SOURCE Life Technologies Corporation
Subscribe to our Free Newsletters!
Do fad diets really work? Here are some disadvantages and side-effects of going on a fad diet. ...
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...